Employees: 901
Size Beijing SL Pharmaceutical (002038.SZ) is a China Health Care company (Biotechnology) with a market value of $736M, the 2779th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.86 on 18 Nov 2026.
Performance Over six months the shares fell 20.5%, against -19.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 3.9% over the last twelve months (peer median +17.1%); the operating margin is -118.9% (peer median -76.8%).
Valuation It trades at 6.9× enterprise value to sales against a peer median of 8.7× (9th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -11%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.6 points below its cost of capital (5.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥556M | CN¥622M | CN¥658M | CN¥1.01B | CN¥1.05B |
| Revenue growth | — | -5% | -35% | -4% | — |
| Gross profit | CN¥347M | CN¥241M | CN¥315M | CN¥703M | CN¥803M |
| EBITDA | n/a | -CN¥462M | CN¥175M | CN¥357M | CN¥258M |
| Net income | -CN¥838M | -CN¥347M | -CN¥74.1M | CN¥417M | CN¥234M |
| Free cash flow | CN¥551M | CN¥111M | -CN¥88.2M | CN¥275M | CN¥260M |
| Capital expenditure | CN¥56.9M | CN¥193M | CN¥347M | CN¥218M | CN¥163M |
| Total debt | CN¥21.4M | CN¥26.0M | CN¥1.26M | CN¥37.6M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002038.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -6.2% | 9th lowest of 21 |
| 6-month return | -20.5% | -19.3% | 10th highest of 19 |
| Distance from 52-week high | -48.3% | -45.5% | 9th lowest of 21 |
| Revenue growth (TTM) | -3.9% | +17.1% | 7th lowest of 15 |
| Operating margin | -118.9% | -76.8% | 7th lowest of 17 |
| EV / Sales | 6.9× | 8.7× | 9th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -13.5% | 28.8% | least demanding of 5 |
| Growth delivered (Del g) | -10.9% | +13.3% | lowest of 5 |
| Hurdle (Req g minus delivered) | -2.6 pp | +12.1 pp | least demanding of 5 |
| ROIC minus cost of capital | -16.6 pp | -24.4 pp | 6th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |